Clinical Trial Update: 18F-PSMA-1007 PET/CT Imaging in Patients with Biochemically Recurrent or High-risk Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating 18F-PSMA-1007 PET/CT imaging in biochemically recurrent or high-risk prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• 18F-PSMA-1007 (PSMA-1007 radiotracer)

Snippet

Sponsor: University of Alberta | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED